NeoGenomics, Inc. (NEO): Price and Financial Metrics
NEO Price/Volume Stats
| Current price | $13.60 | 52-week high | $21.22 |
| Prev. close | $13.77 | 52-week low | $11.03 |
| Day low | $13.52 | Volume | 282,161 |
| Day high | $13.79 | Avg. volume | 895,927 |
| 50-day MA | $15.09 | Dividend yield | N/A |
| 200-day MA | $15.47 | Market Cap | 1.74B |
NEO Stock Price Chart Interactive Chart >
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record DecemberThe S&P 500 came within inches of a record high Thursday, but had to settle for a minute gain as the stock market faded and small caps broke a trend of outperformance. The S&P 500 climbed less than 0.1%. The Nasdaq composite closed fractionally lower after erasing modest gains. |
NeoGenomics to Appeal RulingFORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary ... |
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy ResponseFT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual ... |
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare ConferenceFT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New ... |
Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
NEO Price Returns
| 1-mo | -12.48% |
| 3-mo | -13.54% |
| 6-mo | -2.16% |
| 1-year | -14.36% |
| 3-year | -71.51% |
| 5-year | -30.82% |
| YTD | -15.95% |
| 2023 | 75.11% |
| 2022 | -72.92% |
| 2021 | -36.63% |
| 2020 | 84.07% |
| 2019 | 131.96% |
Continue Researching NEO
Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...